ACP
APLT

Altitude Crest Partners’s Applied Therapeutics APLT Stock Holding History

Altitude Crest Partners’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-259,700
Closed -$1.77M – 5
2024
Q1 		$1.77M Buy
+259,700
New +$1.17M 0.76% 25

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altitude Crest Partners's APLT Position: Q2 2024 in Review

Altitude Crest Partners sold out of Applied Therapeutics (APLT) in Q2 2024, closing a stake of 259,700 shares — an estimated $1.77M sold.

Altitude Crest Partners first reported a position in APLT in Q1 2024 and held it in 1 quarter. The position peaked at $1.77M in Q1 2024. 94 funds tracked by Wall St. Rank hold APLT as of Q2 2024.

  • Altitude Crest Partners reported no remaining Applied Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 259,700 Applied Therapeutics shares in Q2 2024, an estimated $1.77M.
  • Altitude Crest Partners first reported a position in Applied Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Applied Therapeutics position peaked at $1.77M in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.